Found: 62
Select item for more details and to access through your institution.
The Conundrum of Genetic "Drivers" in Benign Conditions.
- Published in:
- 2016
- By:
- Publication type:
- journal article
A phase i study of ixazomib and erlotinib in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 1, p. 99, doi. 10.1007/s10637-021-01153-y
- By:
- Publication type:
- Article
Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 3, p. 416, doi. 10.1007/s10637-017-0513-5
- By:
- Publication type:
- Article
Association of age, gender, and weight on maintenance dose of intravenous unfractionated heparin.
- Published in:
- American Journal of Hematology, 2010, v. 85, n. 8, p. 624, doi. 10.1002/ajh.21751
- By:
- Publication type:
- Article
Carcinoma of unknown primary: Molecular tumor board‐based therapy.
- Published in:
- CA: A Cancer Journal for Clinicians, 2022, v. 72, n. 6, p. 510, doi. 10.3322/caac.21748
- By:
- Publication type:
- Article
Therapeutic Implications of Epidermal Growth Factor Receptor (EGFR) in the Treatment of Metastatic Gastric/GEJ Cancer.
- Published in:
- Frontiers in Oncology, 2020, v. 10, p. N.PAG, doi. 10.3389/fonc.2020.01312
- By:
- Publication type:
- Article
Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study.
- Published in:
- Genome Medicine, 2021, v. 13, n. 1, p. 1, doi. 10.1186/s13073-021-00969-w
- By:
- Publication type:
- Article
MHC-I genotype and tumor mutational burden predict response to immunotherapy.
- Published in:
- Genome Medicine, 2020, v. 12, n. 1, p. 1, doi. 10.1186/s13073-020-00743-4
- By:
- Publication type:
- Article
The paradox of cancer genes in non-malignant conditions: implications for precision medicine.
- Published in:
- Genome Medicine, 2020, v. 12, n. 1, p. 1, doi. 10.1186/s13073-020-0714-y
- By:
- Publication type:
- Article
Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease.
- Published in:
- International Journal of Molecular Sciences, 2017, v. 18, n. 8, p. 1663, doi. 10.3390/ijms18081663
- By:
- Publication type:
- Article
ALK fusions in the pan-cancer setting: another tumor-agnostic target?
- Published in:
- NPJ Precision Oncology, 2023, v. 7, n. 1, p. 1, doi. 10.1038/s41698-023-00449-x
- By:
- Publication type:
- Article
ALK fusions in the pan-cancer setting: another tumor-agnostic target?
- Published in:
- NPJ Precision Oncology, 2023, v. 7, n. 1, p. 1, doi. 10.1038/s41698-023-00449-x
- By:
- Publication type:
- Article
TIM-3 transcriptomic landscape with clinical and immunomic correlates in cancer.
- Published in:
- American Journal of Cancer Research, 2024, v. 14, n. 5, p. 2493, doi. 10.62347/MQFF6404
- By:
- Publication type:
- Article
The transcriptomic expression pattern of immune checkpoints shows heterogeneity between and within cancer types.
- Published in:
- American Journal of Cancer Research, 2024, v. 14, n. 5, p. 2240, doi. 10.62347/JRJP7877
- By:
- Publication type:
- Article
Transcriptomic analysis of GITR and GITR ligand reveals cancer immune heterogeneity with implications for GITR targeting.
- Published in:
- American Journal of Cancer Research, 2024, v. 14, n. 4, p. 1634, doi. 10.62347/ECED5481
- By:
- Publication type:
- Article
High CTLA-4 transcriptomic expression correlates with high expression of other checkpoints and with immunotherapy outcome.
- Published in:
- Therapeutic Advances in Medical Oncology, 2024, p. 1, doi. 10.1177/17588359231220510
- By:
- Publication type:
- Article
Clinical and Biologic Correlates of ADORA2A Transcriptomic Expression in Cancer.
- Published in:
- International Journal of Molecular Sciences, 2024, v. 25, n. 9, p. 4742, doi. 10.3390/ijms25094742
- By:
- Publication type:
- Article
OX40/OX40 ligand and its role in precision immune oncology.
- Published in:
- Cancer & Metastasis Reviews, 2024, v. 43, n. 3, p. 1001, doi. 10.1007/s10555-024-10184-9
- By:
- Publication type:
- Article
BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study.
- Published in:
- NPJ Precision Oncology, 2023, v. 7, n. 1, p. 1, doi. 10.1038/s41698-022-00341-0
- By:
- Publication type:
- Article
Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy.
- Published in:
- NPJ Precision Oncology, 2022, v. 6, n. 1, p. 1, doi. 10.1038/s41698-022-00309-0
- By:
- Publication type:
- Article
Case series of outcomes in advanced cancer patients with single pathway alterations receiving N-of-One therapies.
- Published in:
- NPJ Precision Oncology, 2022, v. 6, n. 1, p. 1, doi. 10.1038/s41698-022-00259-7
- By:
- Publication type:
- Article
Liquid biopsy: current technology and clinical applications.
- Published in:
- Journal of Hematology & Oncology, 2022, v. 15, n. 1, p. 1, doi. 10.1186/s13045-022-01351-y
- By:
- Publication type:
- Article
Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response.
- Published in:
- 2022
- By:
- Publication type:
- Case Study
Multi‐omic analysis in carcinoma of unknown primary (CUP): therapeutic impact of knowing the unknown.
- Published in:
- Molecular Oncology, 2024, v. 18, n. 4, p. 956, doi. 10.1002/1878-0261.13293
- By:
- Publication type:
- Article
Multi‐omic analysis in carcinoma of unknown primary (CUP): therapeutic impact of knowing the unknown.
- Published in:
- Molecular Oncology, 2024, v. 18, n. 4, p. 956, doi. 10.1002/1878-0261.13293
- By:
- Publication type:
- Article
Concordance between cancer gene alterations in tumor and circulating tumor DNA correlates with poor survival in a real‐world precision‐medicine population.
- Published in:
- Molecular Oncology, 2023, v. 17, n. 9, p. 1844, doi. 10.1002/1878-0261.13383
- By:
- Publication type:
- Article
Precision medicine-based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience.
- Published in:
- Molecular Oncology, 2022, v. 16, n. 13, p. 2575, doi. 10.1002/1878-0261.13202
- By:
- Publication type:
- Article
Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients.
- Published in:
- Molecular Oncology, 2021, v. 15, n. 1, p. 67, doi. 10.1002/1878-0261.12791
- By:
- Publication type:
- Article
Heparin-induced thrombocytopenia: analysis of risk factors in medical inpatients.
- Published in:
- British Journal of Haematology, 2011, v. 154, n. 3, p. 373, doi. 10.1111/j.1365-2141.2011.08746.x
- By:
- Publication type:
- Article
Neuregulin-1 and ALS19 (ERBB4): at the crossroads of amyotrophic lateral sclerosis and cancer.
- Published in:
- BMC Medicine, 2024, v. 22, n. 1, p. 1, doi. 10.1186/s12916-024-03293-3
- By:
- Publication type:
- Article
Comparative Genomic Analysis of Intrahepatic Cholangiocarcinoma: Biopsy Type, Ancestry, and Testing Patterns.
- Published in:
- Oncologist, 2021, v. 26, n. 9, p. 787, doi. 10.1002/onco.13844
- By:
- Publication type:
- Article
Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation.
- Published in:
- Oncologist, 2021, v. 26, n. 7, p. e1104, doi. 10.1002/onco.13758
- By:
- Publication type:
- Article
KRAS‐Mutated, Estrogen Receptor‐Positive Low‐Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery.
- Published in:
- Oncologist, 2021, v. 26, n. 4, p. e530, doi. 10.1002/onco.13702
- By:
- Publication type:
- Article
Attrition of Patients on a Precision Oncology Trial: Analysis of the I‐PREDICT Experience.
- Published in:
- Oncologist, 2020, v. 25, n. 11, p. e1803, doi. 10.1002/onco.13532
- By:
- Publication type:
- Article
Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
- Published in:
- Oncologist, 2020, v. 25, n. 2, p. 94, doi. 10.1634/theoncologist.2019-0636
- By:
- Publication type:
- Article
Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach.
- Published in:
- Oncologist, 2018, v. 23, n. 2, p. 171, doi. 10.1634/theoncologist.2017-0199
- By:
- Publication type:
- Article
Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center.
- Published in:
- Oncologist, 2017, v. 22, n. 6, p. 631, doi. 10.1634/theoncologist.2016-0517
- By:
- Publication type:
- Article
A window-of-opportunity biomarker study of etodolac in resectable breast cancer.
- Published in:
- Cancer Medicine, 2015, v. 4, n. 10, p. 1583, doi. 10.1002/cam4.512
- By:
- Publication type:
- Article
Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy.
- Published in:
- Nature Communications, 2020, v. 11, n. 1, p. N.PAG, doi. 10.1038/s41467-020-18613-3
- By:
- Publication type:
- Article
EGFR-Mediated Carcinoma Cell Metastasis Mediated by Integrin αvβ5 Depends on Activation of c-Src and Cleavage of MUC1.
- Published in:
- PLoS ONE, 2012, v. 7, n. 5, p. 1, doi. 10.1371/journal.pone.0036753
- By:
- Publication type:
- Article
Dose‐escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF‐mutated advanced cancers.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 3, p. 391, doi. 10.1002/cncr.33242
- By:
- Publication type:
- Article
Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Dosing of 3 Targeted Agents in Novel Drug Combinations Used at the Precision Medicine Clinic of the University of California San Diego.
- Published in:
- Journal of Hematology Oncology Pharmacy, 2023, v. 13, n. 1, p. 19
- By:
- Publication type:
- Article
An integrin β<sub>3</sub>-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.
- Published in:
- Nature Cell Biology, 2014, v. 16, n. 5, p. 457, doi. 10.1038/ncb2953
- By:
- Publication type:
- Article
Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer.
- Published in:
- Journal of Hematology & Oncology, 2019, v. 12, n. 1, p. N.PAG, doi. 10.1186/s13045-019-0824-4
- By:
- Publication type:
- Article
Relationship between proteinuria and venous thromboembolism.
- Published in:
- Journal of Thrombosis & Thrombolysis, 2010, v. 30, n. 3, p. 281, doi. 10.1007/s11239-010-0442-z
- By:
- Publication type:
- Article
T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapy.
- Published in:
- NPJ Genomic Medicine, 2023, v. 8, n. 1, p. 1, doi. 10.1038/s41525-023-00359-8
- By:
- Publication type:
- Article
Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis.
- Published in:
- NPJ Genomic Medicine, 2023, v. 8, n. 1, p. 1, doi. 10.1038/s41525-022-00346-5
- By:
- Publication type:
- Article
Pan-cancer analysis of TIM-3 transcriptomic expression reveals high levels in pancreatic cancer and interpatient heterogeneity.
- Published in:
- Cancer Medicine, 2024, v. 13, n. 1, p. 1, doi. 10.1002/cam4.6844
- By:
- Publication type:
- Article
LAG‐3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 12, p. 13155, doi. 10.1002/cam4.6000
- By:
- Publication type:
- Article